WinetteVanDerGraaf
@Winette_vdGraaf
Followers
3K
Following
6K
Media
485
Statuses
4K
Medical Oncologist @NKI_nl Amsterdam. Sarcoma; AYA cancer. Prof. @ErasmusMC President of @EORTC, chair @AYAzorgnetwerk @COMPRAYA_study @strong_AYA
Amsterdam, Rotterdam
Joined November 2014
RT @ballingermandy: @OmicoAustralia very own @ProfDMThomas, Cancer Institute NSW Cancer Researcher of the Year. We’re very proud https….
0
5
0
RT @RLRandallMD: Kudos to Robert Maki,MD,past President of @ctos, an extraordinary person & med onc for giving the annual Nina Axelrad Lect….
0
11
0
RT @OncoAlert: The current and future global burden of cancer among adolescents and young adults: a population-based study Out on Lancet On….
0
9
0
RT @ctosociety: With >1000 participants and >500 abstracts presented - #CTOS2024 is the biggest platform connecting anyone interested in sa….
0
19
0
RT @pawel_sobczuk: @DCalleMD presenting validation of CINSARC in pts with retroperitoneal sarcoma.🔸CINSARC is prognostic for OS and DFS.🔸CI….
0
6
0
RT @pawel_sobczuk: Most awaited presentation of the year by @schoffski - BRIGTHLINE-1 trial - Brigimadlin 🆚 doxo in 1st line DDLPS.❌negativ….
0
15
0
Last week I had the pleasure to visit @TataMemorial Mumbai for the @CancerGridIndia meeting and a subsequent meeting with the great #sarcoma team discussing #precisionmedicine and challenging cases. Common practices, but also different (available) treatment options. Interesting!
2
4
22
RT @EORTC: 💻Join us online for the EORTC #PatientDays!. In the 3rd session on #ClinicalTrials we will discuss the objectives and endpoints….
0
1
0
RT @EORTC_QLG: 📰The report from the @EMA_News and @EORTC joint workshop on patient-reported outcomes (PRO) and health-related #QualityofLif….
0
4
0
@HorizonEU @UKRI_News @EuropeanCancer @OlgaHusson @SimoneHanebaum @Janssen_Silvie @NKI_nl.@CancerEurope .@MAASTROclinic @Unimaas .@iknl @EuropeanCancer @EORTC .@asdarlington @unisouthampton .@rgfeltbower @UniversityLeeds @UniversityManch .@GustaveRoussy .@CLCCLeonBerard .@IstTumori .@ILugowska.
0
0
1
1
1
1
We had an amazing annual GA meeting of @strong_AYA in Maastricht. Great to see the progress made over last year in the different work packages. The #AYA patient advisory board did an inspiring mental exercise with us to stress what Cancer at Young Adult age really means for them
2
2
6
Thank you @jeanyvesblay for your excellent talk at the @cddf_eu - @EORTC workshop #RareCancers. You last slides summarized it so well
0
3
19
RT @EORTC: Join us today at the CDDF workshop for the session on innovative trial designs, chaired by @Winette_vdGraaf, including Denis Lac….
0
1
0
So we started with @cddf_eu - @EORTC workshop on #RareCancers in Amsterdam with Francesco Pignatti @EMA_News .Patients unmet needs are obvious!. How can RWD and trials support evidence together? We need to think in an innovative way.
0
1
9
Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs .
0
3
9
Such a great pleasure to have @ProfDMThomas from Sydney @UNSW @OmicoAustralia in Amsterdam. Today @NKI_nl he presented his amazing work: “Moving precision oncology from research to clinical practice for rare cancers”. Nice presentations by our PhDstudents #AYA #sarcoma later on
2
5
22
Such studies need to have QoL assessments, the more so because it is well known how toxic regorafenib is. Not a sweaty after doxorubicin. I wonder whether patients were involved in the design of the study. It’s only a statistically significant positive study ( PFS).
Regorafenib vs placebo as maintenance therapy after doxorubicin-based chth in 1st line #sarcoma.🔸PFS HR 0.53, no benefit in OS.🔸28% stooped regorafenib due to tox.🔸G3-4 tox >60% .Positive study but not practice changing (risk>benefit).#ESMO24 #ESMOAmbassadors @myESMO
0
2
16